Pfizer's CEO Sends a Warning to Eli Lilly. Is the Stock a Buy?

The fast-growing weight-management market has prompted Pfizer to acquire Metsera for $7 billion in cash (up to $10 billion with milestones) after outbidding Novo Nordisk; Metsera’s lead candidate MET‑097i showed substantial phase‑2 weight loss with good tolerability, and CEO Albert Bourla has signaled Pfizer will aggressively scale an obesity franchise with a first anti‑obesity launch targeted by end‑2028. Eli Lilly remains the category leader today—Zepbound is already on the market and near‑term pipeline assets such as oral GLP‑1 orforglipron (potential approval early next year) and triple‑agonist retatrutide keep Lilly well positioned—so Pfizer faces an uphill battle to displace it. Given recent disappointing results and an upcoming Eliquis patent cliff, Pfizer’s turnaround hinges on realizing Metsera’s promise and other pipeline programs (including oncology); the article’s author views Pfizer’s shares as attractive at current levels given the pipeline and dividend profile.

Analysis

Pfizer completed a $7 billion cash acquisition of Metsera (up to $10 billion with milestones) after outbidding Novo Nordisk, acquiring MET-097i which showed substantial weight loss and encouraging tolerability in a phase 2 study; the deal places Pfizer prominently in the fast-growing weight-management market. CEO Albert Bourla framed the effort as a major strategic push, targeting a first anti-obesity launch by the end of 2028, and the company’s prior scale (COVID peak revenue near $57 billion in 2022) and strong dividend program are cited as supporting factors for a turnaround.

Eli Lilly currently leads the category with marketed Zepbound and several near-term pipeline catalysts: orforglipron (oral GLP-1) with strong phase 3 results and a potential approval early next year enabled by an FDA expedited-review voucher, plus phase 3 programs for retatrutide and a phase 3 start for eloralintide next month. Because Lilly has multiple near-term launches and demonstrated market traction, Pfizer faces an uphill multi-year battle to materially displace Lilly’s leadership despite Metsera’s promising mid-stage asset.

Market signals around this news are mildly positive (sentiment score 0.32, market impact 0.42) reflecting upside potential but also execution risk; key investor watchpoints are Metsera’s transition to phase 3 and regulatory milestones, the timing and impact of Lilly’s upcoming approvals, and Pfizer’s broader pipeline (including oncology) plus the looming Eliquis patent cliff that could pressure revenues if new products underperform.

Key Decisions for Investors

• Consider a modest, long-term position in Pfizer to capture potential upside from Metsera and other pipeline programs while sizing positions conservatively pending phase 3 and regulatory readouts
• Maintain or add exposure to Eli Lilly given current market leadership, Zepbound sales momentum and near-term catalysts (orforglipron potential approval early next year and forthcoming retatrutide phase 3 data)
• Monitor clinical and regulatory milestones closely—MET-097i progression to phase 3, FDA review timelines for orforglipron, and retatrutide results—as these are primary re-rating catalysts
• Hedge or limit exposure to Pfizer around the Eliquis patent cliff and execution risk; reassess if Pfizer’s planned 2028 launch timetable slips or if Metsera assets fail to replicate phase 2 tolerability and efficacy